1-4 of 4
Authors: Ruth Katumba
Journal Article
CTIM-24. PHASE II TRIAL OF RHIL-7-HYFC IN PATIENTS WITH HIGH-GRADE GLIOMA DEMONSTRATED ACCEPTABLE SAFETY PROFILE AND REDUCED LYMPHOPENIA
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Pages viii90–viii91, https://doi.org/10.1093/neuonc/noae165.0357
Published: 11 November 2024
Journal Article
CTIM-30. NT-I7, A LONG-ACTING INTERLEUKIN-7, PROMOTES ACTIVATION, CYTOTOXIC FUNCTION, AND SELECTIVE CLONOTYPE EXPANSION OF CD8+ T CELLS IN PATIENTS WITH HIGH GRADE GLIOMAS
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii92, https://doi.org/10.1093/neuonc/noae165.0363
Published: 11 November 2024
Journal Article
CTIM-26. PHASE I/II STUDY OF THE COMBINATION OF PEMBROLIZUMAB (MK-3475) AND LASER INTERSTITIAL THERMAL THERAPY (LITT) IN RECURRENT GLIOBLASTOMA
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi56, https://doi.org/10.1093/neuonc/noab196.218
Published: 12 November 2021
Journal Article
CTIM-07. A PHASE I/II STUDY EVALUATING THE SAFETY AND EFFICACY OF A NOVEL LONG-ACTING INTERLEUKIN-7, NT-I7, FOR PATIENTS WITH NEWLY DIAGNOSED HIGH-GRADE GLIOMAS AFTER CHEMORADIOTHERAPY
Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi50, https://doi.org/10.1093/neuonc/noab196.199
Published: 12 November 2021
